Patricia Pozo Rosich (Headache Unit and Headache Research Group, Vall d’Hebron University Hospital, Barcelona, Spain) talks to us about unmet needs of migraine prevention in Europe and the calcitonin gene-related peptide receptor antagonist, erenumab, in light of it recently receiving a positive CHMP opinion for this indication.
1. What are the major unmet needs of migraine prevention in Europe? (0:12)
2. What is the mechanism of action of erenumab? (0:50)
3. How is erenumab administered? (1:44)
4. Could you tell us a little about the evidence base for the positive CHMP opinion for erenumab for the prevention of migraine? (2:08)
5. Which patients are most likely to benefit from erenumab? (2:39)
Speaker disclosure: Patricia Pozo Rosich serves as a speaker/adviser for Allergan, Almirall, Chiesi, Novartis, Teva and Lilly; she also receives grant support from Allergan.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
Share this Video
Related Videos In Headache Disorders
Robert Music, The Migraine Trust: Improving migraine care – ensuring patient-focussed diagnosis and treatment in the UK
“Migraine is a common and complex brain disorder that affects 10 million people in the UK, impacting their ability to work, relationships and mental health. It’s poorly understood by the public and even many health professionals, and there are challenges around diagnosis, care and access to the right treatment. ” – Rob Music, CEO, The […]
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!